GYKI 52466 dihydrochloride

Research use only, not for human use.

GYKI 52466 is a selective, non-competitive, orally active AMPA receptor (AMPAR) antagonist with IC50 of 10-20 uM against AMPA-induced responses.

GYKI 52466 is a selective, non-competitive, orally active AMPA receptor (AMPAR) antagonist with IC50 of 10-20 uM against AMPA-induced responses; displays >20-fold selectivity over kainate and NMDA receptors; shows anticonvulsant and neuroprotective properties.Alzheimer Disease Discontinued.

GYKI 52466 (0.3-100 μM) inhibits inward currents activated by AMPA and Kainate receptor in cultured rat hippocampal neurons.

GYKI 52466 (intraperitoneal injection; 1.76-13.2 mg/kg; once) treatment provides potent anticonvulsant protection against sound-induced seizures in DBA/2 mice. Animal Model:Male and female DBA/2 mice tested for sound-induced seizure responses Dosage:1.76-13.2 mg/kg Administration:Intraperitoneal injection; 1.76-13.2 mg/kg; once Result:Observed Maximal anticonvulsant protection after the i.p. treatment (5-15 min ).

GYKI52466 dihydrochloride

Membrane Transporter/Ion Channel

iGluR

iGluR

Neurological Disease

Alzheimer Disease

102771-26-6

366.24

C17H15N3O2.2HCl

>98% (HPLC)

——

NC1=CC=C(C2=NN=C(C)CC3=CC4=C(OCO4)C=C32)C=C1

4-(8-Methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-benzenamine dihydrochloride

(-20℃)

With Ice Pack

≥ 2 years